CV

Curriculum Vitae of A/Prof Andrew Kneebone

PERSONAL DETAILS

Name:                                    A/Prof Andrew Bailey Kneebone

 

Qualifications:

M.B.B.S. (University of NSW) – February 1989

Fellow Royal Australian and New Zealand College of Radiologists – October 1996

 

1)General overview

 

A/Prof Andrew Kneebone is a senior staff specialist in radiation oncology at Royal North Shore Hospital Sydney. He has subspecialty interests in gastro-intestinal and genito-urinary malignancies with a strong commitment to research and education.

Achievements in genito-urinary cancers include:

  • In 2006 convened a national consensus conference on the delivery of post prostatectomy radiotherapy the outcomes of which have been published in an international journal. Now regarded as a leading Australian authority on the subject and have been invited speaker at multiple meetings on this topic.
    • Australian chair of “RAVES” trial. Radiotherapy – Adjuvant versus Early Salvage. A randomised trial investigating the optimal timing of post prostatectomy radiotherapy for high risk prostate cancer patients. Trial has secured $2.4million in competitive funding to date and by late 2012 has randomised 230 patients.
  • Secretary of the NSW Genitourinary oncology group for 6 years and convenor of multiple national conferences related to urologic oncology
  • Have been the Principal Investigator in two completed randomised prostate cancer trials which have been published in international journals. The first trial explored whether oral sucralfate reduced bowel complications from prostate radiotherapy and the second evaluated the effectiveness of rigid immobilisation during prostate radiotherapy.
  • Published the only Australian results in the modern era on prostate cancer radiotherapy in 2003 and have presented in 2010 another series of more than 1100 prostate patients who received dose escalated radiotherapy.
  • Member of the Faculty of Radiation Oncology Genito-Urinary Executive since 2004 and integrally involved in developing national radiation oncology guidelines for genitourinary cancers.
  • Involved in multiple NHMRC prostate committees reviewing and writing national guidelines and well as consumer booklets.
  • Awarded funding ($120,000) from the NSW Cancer Institute in 2006 for a Genito-urinary fellow to develop state wide radiation oncology protocols.
  • In 2009, co-convenor for another consensus conference on advanced radiotherapy techniques for prostate and bladder cancer. Co-author on national guidelines published in 2010
    • Member of scientific committee on successful TROG RADAR study due to publish results in 2014.
    • Chief Investigator for successful NHMRC partnership grant in 2011 – improving evidence based care for locally advanced prostate cancer (APP1011474)

 

Achievements in gastro-intestinal cancers include:

  • Secretary of the South Western Sydney Colo-Rectal Tumour Group from 1998 to 2008 supervising a database of nearly 3000 colorectal cancer cases.
  • Deputy chair for the NSW Cancer Institute colorectal group 2006-2010.
  • Member advisory board for the NSW Cancer Council Colorectal Cancer Care Survey.
  • Member scientific committee for successful TROG 98.01 study evaluating preoperative radiotherapy with protracted infusion 5-fluorouracil for resectable adenocarcinoma of rectum.  Member scientific committee for TROG 03.01 study. A randomised phase III study in advanced oesophageal cancer to compare quality of life and palliation of dysphagia in patients treated with radiotherapy versus chemo-radiotherapy. Completed accrual 2012.
  • Member scientific committee for AGITG /NHMRC gastric study “TOP GEAR”. A randomised phase II/III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer. Associate investigator for successful cancer Australia grant of $596,625 and NHMRC grant 2012 for $2,000,000.
  • Member scientific committee for LAP 07 pancreatic study. One of the Chief Investigators for a 2008/2009 cancer Australia Grant for the “LAP 07” trial for $518,000. This is a phase III randomised trial for patients with locally advanced adenocarcinoma of the pancreas: Gemcitabine with or without chemoradiotherapy and with or without erlotinib. Supervising radiation oncology quality assurance
  • Member of AGITG radiation oncology executive and convenor of of contouring workshops at Australian Gastro-Intestinal Trials Group Annual Scientific Meetings 2006 and 2008-2102.
  • Coauthor of national guidelines on delivering IMRT for anal canncer

 

Achievements in research include:

  • Have been integrally involved in nearly $4,000,000 in successful grants for research related to gastro-intestinal and genito-urinary research (see grant applications section)
  • Principal investigator in a multi centre randomised trial of more than 300 patients looking at the effectiveness of oral sucralfate in preventing radiation induced rectal injury (received $120,000 external funding)..
  • Principal Investigator of single institution randomised trial investigating rigid immobilisation during prostate radiotherapy
  • Australian chair for a multi centre phase III randomised trial (RAVES) looking at the optimal timing for post prostatectomy radiotherapy which has secured $2.1 million in competitive funding and plans to start in early 2009.
  • Have been involved in numerous other clinical trials and research groups and am an author on more than 40 peer reviewed publications.
  • Member Trans Tasman Radiation Oncology Quality Assurance Committee.
  • Supervisor of NSW CI funded fellowship of Dr Fiona Hegi Johnson who was awarded EviQ Cancer Treatment Protocols Fellowship and Greater Sydney Stereotactic Body Radiotherapy Fellowship in 2011
  • Chief Investigator of NHMRC partnership grant APP1011474_
    Improving evidence based care for locally advanced prostate cancer

 

Achievements in education include:

  • Director of radiation oncology registrar training at RNSH from mid 2008 to present
  • Responsible for undergraduate education in department of radiation oncology RNSH. Take year 1 students for communication tutorials on weekly basis 2009-2012. Provide lectures to year 2 students during oncology block.
  • Direct supervisor for elective medical students in Radiation Oncology RNSH
  • Involved in Clinico-pathologic session on prostate cancer in 2009 -2012
  • Secretary of the NSW Education co-ordinating committee from 1998 to 2005 which oversaw significant changes in radiation oncology registrar training over that time.
  • CoChair of NSW Cancer Institute Radiation Oncology committee developing EVI-Q guidelines
  • Organiser of NSW Branch of Faculty of Radiation Oncology scientific and social meetings for 7 years 2003-2010 (meetings occur 3 times/year)
  • Supervisor of registrar training at Liverpool hospital from 1998 to 2005 contributing to Liverpool hospital’s very highly regarded registrar training programme.
  • Convenor of 8 national conferences and has been on the organising committee for another 12. General educational conferences include being on the conference organising committees for the 1998  COSA ASM,  the combined Medical Oncology Group and Faculty of Radiation Oncology (MOG/FRO) joint meeting in 1998 and for the 2006 and 2008 RANZCR Faculty Radiation Oncology ASM. Was the convenor for the MOG/FRO meeting in 2000, and for the 2005 RANZCR Faculty Radiation Oncology ASM.
  • Strong commitment to undergraduate training establishing a medical student oncology programme at Liverpool hospital between 1998-2000 for University of NSW. Supervised medical student research projects at Liverpool Hospital and also regularly performed as an examiner for year 4 and 6 undergraduate examinations. Gave annual lectures on the principles of oncology and role of radiotherapy for palliation at the University of NSW.
  • Previously Lecturer and co-ordinator of anatomy programme for Basic Sciences of Oncology Course NSW Cancer Council, Co-ordinator Anatomy section of Distance learning Basic Sciences of Oncology Course and Lecturer Cumberland College of Health Sciences

 

 


2) APPOINTMENTS :

 

Dec 2009 – present Clinical Associate Professor with Northern Clinical School, University of Sydney from December 2009 to present
July 2008 – present Senior Staff Specialist Department of Radiation Oncology Royal North Shore Hospital
 2005 – July 2008 Senior Staff Specialist, department of radiation oncology Liverpool Hospital, Liverpool,N.S.W. 
 1998 – 2005

 

Staff Specialist, department of radiation oncology
Liverpool Hospital, Liverpool,N.S.W. 
1997 Clinical fellow and locum staff specialist.
Westmead Hospital, Westmead, N.S.W.
Oct 1992-Jan 1997 Registrar in Radiation Oncology.
Prince of Wales Hospital, Sydney, N.S.W.
1993 – 1997 Part Time Medical Registrar
Mater Misericordiae Hospital North Sydney, N.S.W.
Jan-Sept 1992 Medical Registrar.
Gosford Hospital, Gosford, N.S.W.
1991 Locum Senior House Officer Positions.
United Kingdom (including Mt Vernon Hospital)
1989-1990 Internship and residency.
Westmead Hospital, Sydney, N.S.W.

 

 

 

 

3) SERVICE & LEADERSHIP TO THE PROFESSION, DISCIPLINE, UNIVERSITY AND WIDER COMMUNITY

a) Administrative role in Hospital

  • Director of radiation oncology registrar training at RNSH from mid 2008 to present
  • Responsible for undergraduate education in department of radiation oncology RNSH.
  • Direct supervisor for elective medical students in Radiation Oncology RNSH
  • Take year one medical students on weekly communication tutorials 2009-2012
  • Responsible with Dr Thomas Eade for the management of genito-urinary cancers in the department of radiation oncology RNSH
  • Responsible for the management of upper gastro-intestinal and colorectal cancers in the department of radiation oncology RNSH

 

b) Membership/chairmanship of committees

  • Secretary NSW Genito-Urinary Oncology Group (2000 to 2006)
  • Executive committee for Faculty Radiation Oncology (RANZCR) Genito-Urinary Group (2004 to present)
  • Executive committee NSW Urology Oncology programme (2006 to 2011)
  • Secretary, South Western Sydney Colorectal Tumour Group (1998 – 2008)
  • Member NSW Pancreatic Cancer Network
  • Member of Austraian Gastro-Intestinal Trials Group (AGITG) radiation oncology executive
  • Secretary of the NSW Education co-ordinating committee from 1998 to 2005
  • Chair of Liverpool Cancer Therapy Centre Patient Friendliness Committee
  • Member of TROG Quality Assurance Committee
  • Co-Chair for the NSW Cancer Institute Standard Cancer Treatments Program – Radiotherapy protocols (2007 to 2011)

 

Clinical trial Committees:

 

  • Principal Investigator of multi-centre Randomised trial investigating oral sucralfate during prostate radiotherapy
    As a registrar initiated a phase III multi-centre trial across Sydney involving more than 300 patients looking at the effect of oral sucralfate in reducing acute and late rectal injury. Has been published in International Journal Radiation Oncology Biology Physics
  • Principal Investigator of single institution randomised trial investigating rigid immobilisation during prostate radiotherapy
    During fellowship/locum at Westmead initiated a randomised trial involving 100 patients evaluating rigid immobilisation during prostate radiotherapy. Published in Radiotherapy Oncology
  • Australian chair of “RAVES” trial. Radiotherapy – Adjuvant versus early salvage. (post prostatectomy radiotherapy)
  • Member scientific committee for TROG 98.01 rectal study
  • Member scientific committee for TROG 03.01 oesophageal study
  • Member scientific committee for AGITG /NHMRC gastric study “TOP GEAR”
  • Member scientific committee for LAP 07 pancreatic study
  • Member of scientific committee on TROG RADAR prostate study
  • Member scientific committee for RAVES Decision Aid study

 

 

 

 

c) National/international conferences or symposia organized

  • Member of conference organising committee for 1998 Annual Scientific meeting of COSA
  • Member of conference organising committee for combined Medical Oncology Group and Faculty of Radiation Oncology Joint meetings in 1998 and 2000 (convenor in 2000)
  • Member conference organising committees for genito-urinary oncology group symposiums in 1998 and 2000
  • Convenor SWS Colorectal Tumour Group Clinical and Research Meeting in 2003
  • Convenor 2005 RANZCR Faculty Radiation Oncology ASM
  • Convenor best practice workshop in urologic oncology in 2001,2004, 2007 and 2010
  • Member conference organising committee 2006 and 2008 RANZCR Faculty Radiation Oncology ASM
  • Convenor Consensus workshop on postprostatectomy radiotherapy  and toxicity collection
  • Member conference organising committee 2007, 2008 and 2009 Australian Gastro-Intestinal Trials Group Meetings
  • Co Convenor for FROGG workshop on advanced radiotherapy techniques for prostate cancer in 2009 and high risk prostate cancer in 2012
  • Organiser of NSW Branch of Faculty of Radiation Oncology scientific and social meetings for 7 years (meetings occur 3 times/year)

 

PROFESSIONAL AND COMMUNITY ACTIVITIES

Service on Commonwealth and State Government agencies

  • Member Australian Prostate Cancer Consumer Guidelines working group (2000 & 2006)
  • Member Working Panel to Review Submissions for NHMRC guidelines on Management of Localised Prostate Cancer (2000)
  • Member  NHRMC Advanced Prostate Cancer Guidelines committee
  • Deputy chair, NSW Cancer institute Colorectal Group Executive (2006 to 2010)
  • Co-Chair for the NSW Cancer Institute Standard Cancer Treatments Program – Radiotherapy protocols (2007 to 2011)
  • Member NSW Cancer Council Colorectal Cancer Care Survey Advisory Committee (2005 to present)
  • Member Cancer Clinical Trials Research Organisation – Interim management committee – NSW Cancer Council (2001/2002)


4)Publications:

Adjuvant therapy for rectal cancer can no longer be ignored

M.Barton, A.Kneebone
Editorial, Australia and New Zealand Journal of Surgery (1999) 69,619-621

 

RECTAL CANCER PROBLEM BASED LEARNING MODULE

Kneebone A., Clarke S., Lee P., Loder P., Simons R.

(Distributed by the NSW Cancer Council by late 1998)

 

A phase II trial of preoperative radiotherapy with protracted infusion 5-fluorouracil for resectable adenocarcinoma of rectum.  A multi-center trial for the Trans-Tasman Radiation Oncology Group. 

Ngan SY, Burmeister BH, Fisher R, Rischin D, Schache DJ, Kneebone A, Mackay JR, Joseph DJ, Bell A, Goldstein D.

Int J Radiat Oncol Biol Phys 2000;48 (suppl):119-120.  (Abstract)

 

A PHASE III RANDOMISED TRIAL TO ASSESS THE EFFECT OF ORAL SULCRALFATE ON THE ACUTE PROCTITIS ASSOCIATED WITH PROSTATE RADIOTHERAPY
Kneebone, A; Mameghan, H; Berry, M; Kearsley, J; Turner, S; Bolin, T; Fisher R;Graham P.; Delaney, G.

International Journal  Radiation Oncology Biology Physics. 2001 Nov 1;51(3):628-35.

 

Early toxicity from preoperative radiotherapy with continuous infusion 5-fluorouracil for resectable adenocarcinoma of rectum.  a phase II trial for the trans-tasman radiation oncology group.
Ngan S.Y.K.1, Burmeister B.H.2, Fisher R.1, Rischin D.1, Schache D.J.2, Kneebone A.3, Mackay J.R.1. Joseph D.J.4, Bell A.2, Goldstein D5.
International journal Radiation Biology Physics Vol 50 (4) 883-887, 2001

 

Back pain and metastatic spinal disease: making the diagnosis.
Chong C.C.W., Kneebone A., Sheridan M.
Australian Family Physician Vol. 30, Issue 9. September (9) 863-865, 2001.

 

Managing malignant spinal cord compression.
Chong C.C.W., Kneebone A., Sheridan A.
Australian Family Physician Vol. 30 Issue 9, September (9) 859-861, 2001.

 

TALKING ABOUT SEXUALITY, BODY IMAGE AND CANCER: A TEACHING RESOURCE FOR HEALTH PROFESSIONALS
Contributing author to publication distributed by NSW Cancer Council April 2002

 

Comparison of two regimens of protracted infusion 5-fluorouracil as part of preoperative chemoradiation treatment of resectable adenocarcinoma of rectum. 

Ngan S, Fisher R, Rischin D, Joseph D, Burmeister B, Schache D, Harvey J, Zissiadis Y, Goldstein D, Kneebone A

Radiother Oncol 2001;58 (suppl 1):36.  (Abstract)

 

Randomised trial of complete Immobilization for Pelvic Irradiation

Kneebone A., Hogendorn N.Tramontana D. Gapes L.Turner S. Gebski V.

International Journal Radiation Oncology Biology Physics July 15;56(4):1105-11. 2003

 

 

PROSPECTIVE REVIEW OF OUTCOME FOLLOWING RADICAL IRRADIATION FOR

CLINICALLY LOCALISED PROSTATE CANCER

Kneebone A., Turner S.,.Berry M., Cakir, B. Gebski, V.

Australasian  Radiology 2003 Dec;47(4):422-7

 

Delayed relapse following preoperative chemoradiation and surgery for rectal cancer.
Ngan SY, Fisher R, Burmeister B, Rischin D, Mackay J, Kneebone A, Joseph D, McKendrick J, Goldstein D, McClure B, Lim Joon D.
Int J Radiat Oncol Biol Phys. 2003 Oct 1;57(2 Suppl):S220.

 

COMPUTERISED SCREENING FOR ANXIETY, DEPRESSION AND RADIATION TOXICITY IN CANCER PATIENTS.
Jacob S, Berry M, Kneebone A, Delaney G, Fowler A, Behan S, Barton M.

Cancer Forum 2004, Volume 28 (3): 143 – 146.
Effect of oral sucralfate on late rectal injury associated with radiotherapy for prostate cancer: A double-blind, randomized trial.
Kneebone A, Mameghan H, Bolin T, Berry M, Turner S, Kearsley J, Graham P, Fisher R, Delaney G.
Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1088-97.

 

Three-dimensional conformal radiotherapy in the treatment of prostate cancer in Australia and New Zealand: Report on a survey of radiotherapy centres and the proceedings of a consensus workshop.

Tai KH, Duchesne G, Turner S, Kneebone A, See A, Gogna K, Berry M

Australas Radiol. 2004 Dec;48(4):502-8.

 

AUSTRALIAN AND NEW ZEALAND 3D CONFORMAL RADIATION THERAPY (3DCRT) CONSENSUS GUIDELINES FOR PROSTATE CANCER

Skala M, Berry M, Duchesne G, Gogna K, Tai KH, Turner S, Kneebone A, Rolfo A, Haworth A

Australas Radiol. 2004 Dec;48(4):493-501.

 

Direct comparison of 18F-fluorodeoxyglucose coincidence gamma camera tomography with gallium scanning for the staging of lymphoma

Lin P, Chu J, Kneebone A, Pocock N, Kiat H, Rosenfeld D, Moylan E
Intern Med J. 2005 Feb;35(2):91-6.

 

Australia-wide Comparison of IMRT Prostate Plans
Skala M,  Holloway L, Bailey M, Kneebone A
Australas Radiol. 2005 Jun;49(3):222-9.

 

Promising Results of a Co-operative Group Phase II Trial of Preoperative Chemoradiation for Locally Advanced Rectal Cancer (TROG 9801)

Ngan SY, Fisher R, Burmeister BH, Mackay J, Goldstein D, Kneebone A, Schache D, Joseph D, McKendrick J, Leong T, McClure B, Rischin D.

Dis Colon Rectum. 2005 Jul;48(7):1389-96.

 

SURGICAL MANAGEMENT OF COLORECTAL CANCER IN SOUTH WESTERN SYDNEY1997-2001: A prospective series of 1293 unselected cases from six public hospitals
Wong S K C,  Kneebone A, Morgan M, Henderson C J A, Jalaludin B, Morgan A.
ANZ J Surg. 2005 Sep;75(9):776-82.

Patterns of practice in the management of prostate cancer: results from multidisciplinary surveys of clinicians in Australia and New Zealand in 1995 and 2000.
Chong CCW, Austen L., Kneebone A., Berry M., Lalak A., Moylan E.
British Journal Urology International 2006; 97: 975-980

 

First case report of recurrent synovial chondromatosis treated  with adjuvant radiotherapy.
Chong C.C.W., Kneebone A., Kirsh G.
Australasian Radiology. 2007 Feb;51(1):95-8..

 

LOCALISED PROSTATE CANCER – A GUIDE FOR MEN AND THEIR FAMILIES
Contributing author (steering committee member)
Australian Prostate Cancer Collaboration ISBN 0 9579938-1-1
December 2001 and July 2006 editions

 

Concordance with national guidelines for colorectal cancer care in New South Wales: a population-based patterns of care study.
Young JM, Leong DC, Armstrong K, O’Connell D, Armstrong BK, Spigelman AD, Ackland S, Chapuis P, Kneebone AB, Solomon MJ.
Med J Aust. 2007 Mar 19;186(6):292-5.

 

Utilisation of Radiotherapy for Rectal Cancer in Greater Western Sydney 1994-2001
Hegi-Johnson F., Gabriel G, Kneebone A, Wong S.K C, Jalaludin B, Behan S, Barton M.B.
Asia-Pacific Journal of Clinical Oncology 2007; 3;134-142

 

The New South Wales colorectal cancer care survey – Part 3 Radiotherapy management for rectal cancer.
Armstrong K, Kneebone A, O’Connell DL, Leong D, Yu XQ, Spigelman AD, Armstrong BK. The Cancer Council NSW October 2007.

 

Anatomic boundaries of the clinical target volume (prostate bed) after radical prostatectomy
Wiltshire KL, Brock KK, Haider MA, Zwahlen D, Kong V, Chan E, Moseley J, Bayley A, Catton C, Chung PW, Gospodarowicz M, Milosevic M, Kneebone A, Warde P, Ménard C.
Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):1090-9

 

Late rectal and urinary toxicity from conformal, dose-escalated radiation therapy for prostate cancer: a prospective study of 402 patients.
Lin C, Turner S, Mai T, Kneebone A, Gebski V
Australas Radiol. 2007 Dec;51(6):578-83

 

3D Radiotherapy Can Be Safely Combined with Sandwich Systemic Gemcitabine Chemotherapy in the Management of Pancreatic Cancer: Factors Influencing Outcome.
Spry N, Harvey J, Macleod C, Borg M, Ngan SY, Millar JL, Graham P, Zissiadis Y, Kneebone A, Carroll S, Davies T, Reece WH, Iacopetta B, Goldstein D
Int J Radiat Oncol Biol Phys. 2007 Dec 28

 

Improved Survival in Young Females with Colorectal Cancer
Koo JH, Wong SKC, Jalaludin B, Kneebone A, Connor S, Leong R
Am J Gastroenterol. 2008 Jun;103(6):1488-95

 

Post Prostatectomy Radiation Therapy: Consensus Guidelines of the Australian and New Zealand Radiation Oncology Genito-Urinary Group
Sidhom M,  Kneebone A, Lehman M, Wiltshire K,  Millar J, Mukherjee R, Shakespeare T, Tai KH.
Radiother Oncol. 2008 Jul;88(1):10-9

 

DIRECT TUMOUR INVASION IN COLON CANCER: ITS CORRELATION WITH TUMOUR SPREAD AND SURVIVAL
Wong SKC, Jalaludin B, Henderson C, Morgan M, Berthelsen A, Kneebone A
Dis Colon Rectum. 2008 Jun 13

 

Clinical and Pathological Outcomes of Colorectal Cancer in a Multi-ethnic Population
Koo JH, Wong SKC, Jalaludin B, Kneebone A, Connor S, Leong R
Clin Gastroenterol Hepatol. 2008 Jun 14

 

Accrediting radiation technique in a multicentre trial of chemoradiation for pancreatic cancer.

Spry N, Bydder S, Harvey J, Borg M, Ngan S, Millar J, Graham P, Zissiadis Y, Kneebone A, Ebert M.

J Med Imaging Radiat Oncol. 2008 Dec;52(6):598-604.

 

AN AUSTRALIAN CLINICAL PERSPECTIVE: MANAGEMENT OF HORMONE REFRACTORY (ANDROGEN INDEPENDENT) PROSTATE CANCER.

Hovey E., Marx G., Kneebone A., Patel M., Shapiro J.
Asia Pacific Journal of Oncology and Haematology 2009; 1 :(1) March

 

Impact of a real-time peer review audit on patient management in a radiation oncology department.

Boxer M, Forstner D, Kneebone A, Delaney G, Koh ES, Fuller M, Kaadan N.
J Med Imaging Radiat Oncol. 2009 Aug;53(4):405-11

 

Australian & New Zealand Faculty of Radiation Oncology Genito-Urinary Group: 2010 consensus guidelines for definitive external beam radiotherapy for prostate carcinoma.

Hayden AJ, Martin JM, Kneebone AB, Lehman M, Wiltshire KL, Skala M, Christie D, Vial P, McDowall R, Tai KH; Australian & New Zealand Faculty of Radiation Oncology Genito-Urinary Group.
J Med Imaging Radiat Oncol. 2010 Dec;54(6):513-25. doi: 10.1111/j.1754-9485.2010.02214.x.

 

Risk and response adapted therapy for early stage Hodgkin lymphoma: a prospective multicenter study of the Australasian Leukaemia and Lymphoma Group/Trans-Tasman Radiation Oncology Group.

Wirth A, Grigg A, Wolf M, Goldstein D, Johnson C, Davis S, Dutu G, Kypreos P, Smith C, Kneebone A, Herzberg M, Joseph D, Catalano J, Roos D, Stone J, Reynolds J.
Leuk Lymphoma. 2011 May;52(5):786-95. Epub 2011 Feb 14.

 

 

 

Evaluating the utility of a patient decision aid for potential participants of a prostate cancer trial (RAVES-TROG 08.03).

Sundaresan P, Turner S, Kneebone A, Pearse M, Butow P.
Radiother Oncol. 2011 Dec;101(3):521-4. Epub 2011 Oct 8.

 

Image-guided dose-escalated intensity-modulated radiation therapy for prostate cancer: treating to doses beyond 78Gy.

Eade TN, Guo L, Forde E, Vaux K, Vass J, Hunt P, Kneebone A.
BJU Int. 2011 Oct 28.

 

Australian & New Zealand Faculty of Radiation Oncology Genito-Urinary Group: 2011 consensus guidelines for curative radiotherapy for urothelial carcinoma of the bladder.

Hindson BR, Turner SL, Millar JL, Foroudi F, Gogna NK, Skala M, Kneebone A, Christie DR, Lehman M, Wiltshire KL, Tai KH; on behalf of the RANZCR Faculty of Radiation Oncology Genito-Urinary Group (FROGG).
J Med Imaging Radiat Oncol. 2012 Feb;56(1):18-30.

 

Australasian Gastrointestinal Trials Group (AGITG) Contouring Atlas and Planning Guidelines for Intensity-Modulated Radiotherapy in Anal Cancer.

Ng M, Leong T, Chander S, Chu J, Kneebone A, Carroll S, Wiltshire K, Ngan S, Kachnic L.
Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):1455-62. Epub 2012 Mar 6.

 

Impact of Gemcitabine Chemotherapy and 3-Dimensional Conformal Radiation Therapy/5-Fluorouracil on Quality of Life of Patients Managed for Pancreatic Cancer.
Short M, Goldstein D, Halkett G, Reece W, Borg M, Zissiadis Y, Kneebone A, Spry N.
Int J Radiat Oncol Biol Phys. 2012 Apr 27.

TH-E-BRA-11: Real-Time Tumor Localization with Kilovoltage Intrafraction Monitoring: First Clinical Implementation for Prostate Intensity Modulated Arc Therapy.

Ng J, Booth J, Poulsen P, Eade T, Hegi F, Kneebone A, Kuncic Z, Keall P.
Med Phys. 2012 Jun;39(6):4014.

Re: Andrew J. Stephenson, Michel Bolla, Alberto Briganti, et al. Postoperative Radiation Therapy for Pathologically Advanced Prostate Cancer After Radical Prostatectomy. Eur Urol 2012;61:443-51.
Sydes MR, Vale C, Kneebone A, Pearse M, Richaud P, Tierney JF, Parker CC. Eur Urol. 2012 Sep 11

 

Informed prostate cancer risk-adjusted testing: a new paradigm.
Stricker PD, Frydenberg M, Kneebone A, Chopra S.
BJU Int. 2012 Dec;110 Suppl 4:30-4.

 

Health-related quality of life using intensity-modulated radiation therapy for post-prostatectomy radiotherapy.
van Gysen KL, Kneebone AB, Guo L, Vaux KJ, Lazzaro EM, Eade TN.
J Med Imaging Radiat Oncol. 2013 Feb;57(1):89-96.

5) Presentations (first author only)

Radiation time factors in nasopharyngeal carcinoma

A. Kneebone,  R. Smee,  J. Hyde and R. Fisher.

Presented RANZCR Annual General Meeting Perth 1996.

 

ACUTE RECTAL COMPLICATIONS WITH ARC ROTATION VS A FOUR FIELD  “BOX” TECHNIQUE IN THE TREATMENT OF CARCINOMA OF THE PROSTATE

Kneebone A., Fisher R., Mameghan H., Berry M., Bolin T., Turner S., Kearsley J., Graham P.,  Delaney G. Presented RANZCR Annual General Meeting Adelaide  September 1997)

 

SUCRALFATE AND RADIATION INDUCED BOWEL INJURY – THE DEFINITIVE OVERVIEW
A.Kneebone  Invited speaker for the Radiation Induced Gastro-Intestinal Toxicity Workshop
Port Douglas, Queensland June 1998

 

Locally Advanced Breast Cancer Hypotheticals
Invited speaker at Annual Scientific Meeting for COSA 1998

 

A DOUBLE BLIND RANDOMISED TRIAL TO ASSESS THE EFFECT OF ORAL SULCRALFATE ON THE ACUTE PROCTITIS ASSOCIATED WITH PROSTATE RADIOTHERAPY
Kneebone A., Fisher R., Mameghan H., Berry M., Bolin T., Turner S., Kearsley J.,
Graham P.,  Delaney G.

Presented RANZCR AGM Sydney 1999
Awarded the Medical Applications Prize for the best original research from a fellow of the Faculty of Radiation Oncology

 

ADVANCES IN THE RADIOTHERAPEUTIC MANAGEMENT OF PROSTATE CANCER
Invited speaker at the National Conference of the Medical Oncology Group and the Faculty of Radiation Oncology at Sydney April 2000. Same talk also given at the June meeting of the NSW genito-urinary oncology group

 

The natural history of radiation bowel complications and overview as to the role of SUCRALFATE
Invited speaker for the Radiation Induced Gastro-Intestinal Toxicity Workshop
Port Douglas, Queensland June 2000

 

Role of Radiotherapy for rectal Cancer

Invited speaker for annual colorectal seminar for Nurses and Allied Health
Liverpool Hospital June 1998 -2006.

 

Role of Radiotherapy for the palliation of pain

Invited speaker for Pain Seminar held at Liverpool Hospital 2001

 

Prostate Cancer Education DAY
Invited presenter for education workshop on prostate cancer for the general public organised by the prostate cancer foundation and the SWS Prostate Cancer Support Group. Liverpool Hospital 2001

 

Screening for Prostate Cancer. What’s the current status?
Talk to Bankstown Division of General Practitioners 2001

 

   Nhmrc Guidelines on management of colorectal Cancer
Invited speaker to conduct series of workshops for general practitioners in 2001 aimed at disseminating awareness of colorectal cancer guidelines organised by NSW genetics education unit

A RANDOMISED TRIAL EVALUATING RIGID IMMOBILIZATION FOR PELVIC IRRADIATION.

Kneebone, A, Hogendoorn, Gebski,V, Turner S.

Presented at the 52nd Annual Scientific Meeting of RANZCR 2001, Melbourne.

THE EFFECT OF ORAL SULCRALFATE ON LATE RECTAL INJURY ASSOCIATED WITH PROSTATE RADIOTHERAPY.
Kneebone A., Fisher R., Mameghan H., Berry M., Bolin T., Turner S., Kearsley J.,
Graham P., Delaney G. Presentated at the 52nd Annual Scientific Meeting of RANZCR 2001, Melbourne.

 

Prostate Cancer Imaging
Imaging in Radiation Therapy Planning Interdisciplinary Seminar held at Liverpool Hospital 16th February 2002

 

AUSTRALIAN AND NEW ZEALAND CONSENSUS GUIDELINES FOR 3D CONFORMAL RADIATION THERAPY IN PROSTATE CANCER

Invited speaker to National conference in Melbourne in May 2002 aimed at developing national guidelines for development of consensus guidelines for 3d conformal radiotherapy

 

 

Is Australian Prostate Radiotherapy up to Scratch?

Kneebone A., Turner S.,.Berry M., Cakir, B. Gebski, V.
Presented at the Urological Society of Australasia meeting, March 2003 Queenstown New Zealand

SOUTH WESTERN SYDNEY COLORECTAL TUMOUR GROUP DATABASE. A PRELIMINARY REPORT

Kneebone A, Berthelson A, Jalaludin B, Morgan M, Wong C.

Invited speaker at SWS CRTG clinical and research meeting Bowral March 2003.

 

Feasibility of Daily ultrasound localisation for prostate cancer radiotherapy in Australia
Kneebone A, Fuller M, Williams M.
Presentation at the 12th International congress of radiation research Brisbane August 2003

 

NEW DEVELOPMENTS IN RADIOTHERAPY TARGETING AND VERIFICATION
Invited speaker on BAT ultrasound localisation for this multidisciplinary workshop held at Crowne Plaza Hotel Newcastle February 18,2005

Faculty of Radiation Oncology Genito-Urinary Oncology Group (FROGG) Consensus Guidelines On Post Prostatectomy Radiotherapy
Kneebone A.B.,1 Sidhom M.,1 Lehman M.,2 Wiltshire K.,3 Millar J.L.,4 Mukherjee R.K.,5 Tai K.H.6
Accepted for top proffered papers session 2006 Faculty Of Radiation Oncology ASM Singapore

Who, when and how to give post prostatectomy Radiotherapy
Invited speaker at Best Practice Workshop in Urological Oncology Darling Harbour June 2007

Combining Hormone Therapy  and Radiotherapy
Invited speaker at 8th National Prostate Cancer Symposium Melbourne August 2007

 

Who, when and how to give post prostatectomy Radiotherapy
Invited speaker at Back to POWH meeting Coogee Beach September 2007

 

Convenor Rectal Cancer Contouring Workshop
Australian Gastro-Intestinal Trials Group meeting, Sydney, September 2008

 

Convenor Genito-Urinary and Head and Neck Contouring workshops
59th  Annual Scientific Meeting of RANZCR 2008, Adelaide

 

Current status of Post prostatectomy Radiotherapy
59th  Annual Scientific Meeting of RANZCR 2008, Adelaide

 

POST PROSTATECTOMY CONTOURING WORKSHOP
Conducted post prostatectomy contouring workshop for New Zealand Radiation Oncologists in May 2009 at Christchurch

 

POST PROSTATECTOMY RADIOTHERAPY AND THE RAVES TRIAL

Have been an invited speaker at numerous departments/urology meetings to promote the RAVES trial and discuss post prostatectomy radiotherapy. Departments spoken to include:

1)     Royal North Shore Hospital December 08

2)     Newcastle Mater Hospital February 09

3)     St Vincents Hospital February 2009

4)     Urological Society of Australia ASM Melbourne March 2009

5)     Queensland Urology Chapter meeting Brisbane 2009

6)     St George Hospital April 2009

7)     Prince of Wales Hospital April 2009

8)     Westmead Hospital May 2009

 

Results from SWS Colorectal database and rectal contouring workshop
Liverpool Hospital Gastro-intestinal Seminar June 2009

 

MANAGEMENT OF POSITIVE MARGINS POST PROSTATECTOMY
Invited speaker at 10th National Prostate Cancer Symposium Melbourne August 2009

 

Convenor Radiation oncology Workshop
Australian Gastro-Intestinal Trials Group meeting, Sydney, September 2009

 

Significantly better outcomes seen with contemporary external beam radiotherapy for prostate cancer: A prospective study of 1101patients
Accepted oral presentation at Combined Scientific Meeting of RANZCR  Brisbane October 2009

Are we doing any better with external beam radiotherapy for prostate cancer?
Accepted oral presentation at Annual Scientific meeting of Urological Society of Australia and new Zealand February 2010 Perth

SelectioN, timing and morbidity of post prostatectomy Radiotherapy
Invited speaker at Best Practice Workshop in Urological Oncology Darling Harbour June 2010

 

Cone Beam CT. Useful Tool or Expensive Hype?
Invited speaker 61st  Annual Scientific Meeting of RANZCR 2010, Brisbane

 

Convenor Radiation oncology Workshop on Anal cancer Contouring
Australian Gastro-Intestinal Trials Group meeting, Brisbane, August 2010

 

Radiotherapy post prostatectomy: Adjuvant versus early salvage
Invited speaker North Coast cancer Conference 18-19th March 2011 Coffs harbour

 

Radiation Treatment for Prostate cancer
Invited speaker for NSW Urological Nurses Society Day Burwood 8th April 2011

 

Role of Cone Beam CT for Image Guidance
Invited Speaker for RANZCR Queensland Branch ASM Brisbane 28th May 2011

 

Stereotactic Body Radiotherapy
Invited Speaker for RANZCR Queensland Branch ASM Brisbane 28th May 2011

 

Pancreas Cancer Contouring Workshop
Chair of Pancreas Contouring session at AGITG meeting 24-26th August 2011

 

Clinical Oncological Society of Australia
Invited speaker at plenary session on Advances in Genito-urinary Radiotherapy at Perth in November 2011

 

RAVES TROG studies update
Invited speaker at ANZUP annual general meeting 14-16th July 2012

 

The Use of Intensity Modulated Radiation Therapy For Rectal Cancer Should Not Be Ignored.
Accepted proffered paper at RANZCR Faculty of Radiation Oncology 2012 ASM 26 – 28 July 2012 Cairns.

A clinician’s guide to obtaining the best IMRT plan
Invited plenary speaker at RANZCR Faculty of Radiation Oncology 2012 ASM 26 – 28 July 2012 Cairns.

 

Establishing a stereotactic body programme – lessons learnt and outcomes
Invited plenary speaker at RANZCR Faculty of Radiation Oncology 2012 ASM 26 – 28 July 2012 Cairns.

 

Convenor Radiation oncology Workshop on Gastric cancer Contouring
Australian Gastro-Intestinal Trials Group meeting, Sydney, September 2012.

 

The evolving role of radiotherapy for high risk prostate cancer
Invited speaker at Astra Zeneca meeting Quaff Restaurant Toorak 11th October 2012

The evolving role of post prostatectomy Radiotherapy
Royal Melbourne Hospital Grand Rounds 12th October 2012

 

Obtaining the best IMRT plan
Invited speaker at North Coast cancer Institute Grand Rounds, Lismore 19th October 2012

 

Convenor of IMRT workshop at the Faculty Radiation Oncology High Risk prostate cancer Conference
Henry Jones Art Hotel Hobart 9th November 2012

 

 

 

 

 

 

 

 

6) External funding / grant applications

1998                 $120,000 provided by Chugai pharmaceuticals

`                           For conduct of randomised trial exploring role of oral sucralfate in reducing rectal complications from prostate radiotherapy. (also received financial support from POWH trust funds)

 

1998-2001         $800,000 (approx) from SWS Bowel Cancer Foundation

The SWS Bowel Foundation gave an unconditional donation of this amount to the SWS Colorectal Tumour Group for the establishment of a colorectal database, tumour bank and other educational and research initiatives.

2006                 $120,000 from the NSW Cancer Institiute

Principal Investigator for a competitive grant from the NSW Cancer Institute for a genito-urinary fellow for this amount. Unfortunately the position was not able to be filled and the money had to be refunded.

 

2007                 $177,000 from the NSW Cancer Council

Principal Investigator for a competitive grant from the NSW CC for conduct of RAVES trial in NSW – A phase III trial comparing adjuvant versus salvage radiotherapy for high risk patients post radical prostatectomy

Breakdown:       2008 $79,000
2009 and 2010 $49,000 / year

 

2007                 $296,000 from the Victorian Cancer Council

One of the Chief Investigators for a competitive grant from the Victorian CC for conduct of RAVES trial in Victoria – A phase III trial comparing adjuvant versus salvage radiotherapy for high risk patients post radical prostatectomy

Breakdown:        2008 $100,000
2009  and 2010 $98,000/year

2008                 $775,000 from the NHMRC

Principal Investigator for a competitive grant from the National Health and Medical Research Council for conduct of RAVES trial in Australia – A phase III trial comparing adjuvant versus salvage radiotherapy for high risk patients post radical prostatectomy

Breakdown: $155,000/year 2009 -2013

 

2008                 $1,169,103 NZD from the HRC of New Zealand

One of the Chief Investigators for a competitive grant from the Health  Research Council of new Zealand for conduct of RAVES trial in New Zealand – A phase III trial comparing adjuvant versus salvage radiotherapy for high risk patients post radical prostatectomy

 

2008                 $518,000 Cancer Australia Grant

One of the Chief Investigators for a 2008/2009 cancer Australia Grant for the “LAP 07” trial. This is a phase II randomised trial for patients with  locally advanced adenocarcinoma of the pancreas: Gemcitabine with or without chemoradiotherapy and with or without erlotinib

Breakdown:       2009 $176,000
2010 $196,000
2011 $146,000

 

2008                 $596,625 Cancer Australia Grant (Years 2009-2011)

One of the Associate Investigators for a 2008/2009 cancer Australia Grant for the “Top Gear” trial. This is a randomised phase III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer

 

2009                 $7280 NSW Cancer Institute Grant

For conducting Communications workshop on obtaining informed consent for entering patients into the RAVES trial

 

2010                     $180,000 NSW Cancer Institute Grant 10/CLF/204
Supervisor of Dr Fiona Hegi Johnson who was awarded EviQ Cancer Treatment Protocols Fellowship and Greater Sydney Stereotactic Body Radiotherapy Fellowship

 

2010                     NHMRC partnership grant APP1011474_
Chief Investigator E
Application ID: APP1011474

Title: Improving evidence based care for locally advanced prostate cancer – a randomised phased trial of clinical guideline implementation through a clinical network

Value of grant: $1,071,116 (NHMRC $533,442 / PCFA $537,647)
Number of years: 3
Funding Type: Partnership Grant (Research Support)

 

2012                 $2,000,000 NHMRC Grant (Years 2013-2018)

One of the Associate Investigators for a 2012 NHMRC Grant for the “Top Gear” trial. This is a randomised phase III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer

 

2012                 $130,000 Prostate Cancer Foundation of Australia Grant
Chief Investigator for RAVES Decision Aid study (PI is Puma Sundaresan)